Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | VCP | P55072 | 2/20 | 0.58 |
| ▸ | TLR4 | O00206 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421634 | 1.00 | FBP1 (0.64) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL6910818 | 0.89 | FBP1 (0.78) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL6910815 | 0.89 | FBP1 (0.78) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL1681205 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL366121 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL219464 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL366122 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL1681206 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL2077031 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT | |
| SCHEMBL2077034 | 0.78 | FBP1 (1.00) | FBP1EGFRALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119678922-A | Application of nitrostyrenes compound in preventing, controlling or resisting plant pathogenic nematodes and preparation thereof | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118844436-A | Application of nitrostyrene compound in preventing and treating plant diseases and food-borne pathogenic bacteria | 广西田园生化股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118420514-A | Method for synthesizing 3- (2-nitro-1-aryl) -1H-indole derivative by using cyclopentadienyl titanium/Bronsted acid in synergistic catalysis mode | 宁夏师范学院 | 2024-08-02 | — | — | CN | disclosed |
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2023-06-01 | — | — | US | disclosed |
| CN-115996910-A | Aryl or heteroaryl derivatives | 帝人制药株式会社 | 2023-04-21 | — | — | CN | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| CN-1882590-A | Fused heterocyclic compounds as serotonin receptor modulators | JOHNSON & JOHNSON (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006015827-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| US-4148795-A | Dithiocarbamate ester bactericides and fungicides | AMERICAN CYANAMID COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4038288-A | DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-4011230-A | DITHIOCARBAMATE ESTER BACTERICIDES AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167073-A1 | ARYL OR HETEROARYL DERIVATIVE | ARRB1, NR3C2, TRPC6 | FBP1 3207/4885EGFR 591/4885ALDH1A1 3424/4885 |
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | FBP1 2583/4885EGFR 4669/4885ALDH1A1 4267/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885EGFR 4700/4885ALDH1A1 2953/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | FBP1 426/4885EGFR 2087/4885ALDH1A1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.